Northwest Biotherapeutics Inc: (NASD: NWBO)
$3.58
-0.01 (-0.28%)
Volume 83,918
Jun 19 03:59 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 3.42 - 3.61 |
| 52wk Low - High | 2.98 - 20.00 |
| Previous Close | 3.59 |
| Avg. Volume | 127,906 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 108.08 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.77 |
| P/E (F1) | 0.00 |
| Current Year Est. | -2.02 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
2 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
112 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.02 |
| Current Quarter Estimate | -0.49 |
| Most Accurate Estimate | -0.49 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -4.24 |
| Expected Earnings Growth | NA |
Company Description
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.49 | -0.50 | -2.02 | -1.54 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | -0.49 | -0.50 | -2.02 | -1.54 |
| High Estimate | -0.49 | -0.50 | -2.02 | NA |
| Year Ago EPS | -0.06 | -1.50 | -5.72 | -2.02 |
| EPS Growth | -716.67% | 66.67% | 64.69% | 23.76% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| NORTHWEST BIOTH | NWBO | 3.59 | |
|
| AETERNA ZENTARS | AEZS | 1.90 | |
|
| BIOGEN IDEC INC | BIIB | 210.80 | |
|
| MYRIAD GENETICS | MYGN | 26.44 | |
|
| PROTALIX BIOTHR | PLX | 5.08 | |
|
| ADDEX THERA LTD | ADDXF | 3.95 | |
|
| AFFYMAX INC | AFFY | 1.07 | |
|
| ALEXION PHARMA | ALXN | 92.39 | |
|
| ALNYLAM PHARMA | ALNY | 29.99 | |
|
| ANTHERA PHARMA | ANTH | 0.58 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -4.24 |
| Sales | 1 |
| Net Income | -72 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 118.90 |
News
NW Bio Initiates DCVax-Direct Phase I/II Trial for All Solid Tumor Cancers - Benzinga
Jun 13, 2013
5 Stocks Under $10 Set to Soar - TheStreet.com
Mar 7, 2013
Why Seeking Alpha`s Larry Smith Is Wrong Again About Northwest Bio. - TheStreet.com
Feb 21, 2013
Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma - TheStreet.com
Feb 15, 2013
Micro-Cap on the Move; Northwest Biotherapeutics Inc. (NWBO) - DailyStocks
Jul 27, 2012
Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe - Benzinga
Jul 8, 2011
Northwest Biotherapeutics Announces Change and Expansion of Management Team - Comtex
Jun 9, 2011
Northwest Biotherapeutics Announces Change and Expansion of Management Team - Comtex
Jun 8, 2011
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 7.50 |
| Industry Rank by ABR | 112 out of 265 |
| Rank in Industry | 5 out of 154 |
